Arguments in favour of remdesivir for treating SARS-CoV-2 infections

International Journal of Antimicrobial Agents

Volumn 55, Issue 4, 2020, Pages

  Ko, Wen Chien ^a,b   Rolain, Jean Marc ^c,d   Lee, Nan Yao ^a,b   Chen, Po Lin ^a,b   Huang, Ching Tai ^e   Lee, Ping Ing ^f   Hsueh, Po Ren ^f  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c AIX MARSEILLE UNIVERSITY   (France)

^d IHU MÉDITERRANÉE INFECTION   (France)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Betacoronavirus; Coronavirus disease 2019; COVID 19; Remdesivir; SARS CoV 2; Wuhan pneumonia

Indexed keywords

ACICLOVIR; ARISTEROMYCIN; FAVIPIRAVIR; GALIDESIVIR; PENCICLOVIR; REMDESIVIR; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; ADENOSINE PHOSPHATE; ALANINE; ANTIVIRUS AGENT; DNA DIRECTED RNA POLYMERASE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; DRUG HALF LIFE; DRUG TOLERABILITY; EBOLA HEMORRHAGIC FEVER; EDITORIAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SARS-RELATED CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; ANIMAL; BETACORONAVIRUS; CLINICAL TRIAL (TOPIC); DRUG EFFECT; ENZYMOLOGY; PANDEMIC; VIRUS PNEUMONIA;

ADENOSINE MONOPHOSPHATE; ALANINE; ANIMALS; ANTIVIRAL AGENTS; BETACORONAVIRUS; CLINICAL TRIALS AS TOPIC; CORONAVIRUS INFECTIONS; DNA-DIRECTED RNA POLYMERASES; HUMANS; PANDEMICS; PNEUMONIA, VIRAL;

EID: 85081899519     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2020.105933     Document Type: Editorial

References (24)

1. Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382 (2020), 727–733, 10.1056/NEJMoa2001017.
2. Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med, 2020 Jan 29, 10.1056/NEJMoa2001316 [Epub ahead of print].
3. Chan, J.F., Yuan, S., Kok, K.H., To, K.K., Chu, H., Yang, J., et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395 (2020), 514–523, 10.1016/S0140-6736(20)30154-9.
4. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (2020), 497–506, 10.1016/S0140-6736(20)30183-5.
5. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395 (2020), 507–513, 10.1016/S0140-6736(20)30211-7.
6. Lai, C.C., Shih, T.P., Ko, W.C., Tang, H.J., Hsueh, P.R., Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents, 2020 Feb 17, 105924, 10.1016/j.ijantimicag.2020.105924.
7. Lee, P.I., Hsueh, P.R., Emerging threats from zoonotic coronaviruses—from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect, 2020 Feb 4, 10.1016/j.jmii.2020.02.001 [Epub ahead of print].
8. Gorbalenya A.E., Baker S.C., Baric R.S., de Groot R.J., Drosten C., Gulyaeva A.A., et al. Severe acute respiratory syndrome-related coronavirus: the species and its viruses—a statement of the Coronavirus Study Group. bioRxiv preprint doi: 10.1101/2020.02.07.937862.
9. Chen, Y., Liu, Q., Guo, D., Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 92 (2020), 418–423, 10.1002/jmv.25681.
10. Colson, P., Rolain, J.M., Raoult, D., Chloroquine for the 2019 novel coronavirus. Int J Antimicrob Agents, 2020 Feb 15, 105923, 10.1016/j.ijantimicag.2020.105923.
11. Liu, W., Morse, J.S., Lalonde, T., Xu, S., Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem 21 (2020), 730–738, 10.1002/cbic.202000047.
12. Li, G., Cleraq, E.D., Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Dis, 2020 Feb 19, 10.1038/d41573-020-00016-0.
13. Siegel, D., Hui, H.C., Doerffler, E., Clarke, M.O., Chun, K., Zhang, L., et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f] [triazin-4-amino] adenine c-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem 60 (2017), 1648–1661, 10.1021/acs.jmedchem.6b01594.
14. Pedersen, N.C., Perron, M., Bannasch, M., Montgomery, E., Murakami, E., Liepnieks, M., et al. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg 21 (2019), 271–281, 10.1177/1098612X19825701.
15. Warren, T.K., Jordan, R., Lo, M.K., Ray, A.S., Mackman, R.L., Soloveva, V., et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531 (2016), 381–385, 10.1038/nature17180.
16. Tchesnokov, E.P., Feng, J.Y., Porter, D.P., Götte, M., Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses, 11, 2019, 10.3390/v11040326 pii: E326.
17. Agostini, M.L., Andres, E., Sims, A.C., Graham, R.L., Sheahan, T.P., Lu, X., et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio, 9, 2018, 10.1128/mBio.00221-18 pii: e00221-18.
18. Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020 Feb 4, 10.1038/s41422-020-0282-0.
19. Lo, M.K., Jordan, R., Arvey, A., Sudhamsu, J., Shrivastava-Ranjan, P., Hotard, A.L., et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep, 7, 2017, 43395, 10.1038/srep43395.
20. Sheahan, T.P., Sims, A.C., Graham, R.L., Menachery, V.D., Gralinski, L.E., Case, J.B., et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med, 9, 2017, 10.1126/scitranslmed.aal3653 pii: eaal3653.
21. Brown, A.J., Won, J.J., Graham, R.L., Dinnon, K.H. 3rd, Sims, A.C., Feng, J.Y., et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res, 169, 2019, 104541.
22. Jacobs, M., Rodger, A., Bell, D.J., Bhagani, S., Cropley, I., Filipe, A., et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 338 (2016), 498–503, 10.1016/S0140-6736(16)30386-5.
23. Mulangu, S., Dodd, L.E., Davey, R.T. Jr, Tshiani Mbaya, O., Proschan, M., Mukadi, D., et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 381 (2019), 2293–2303, 10.1056/NEJMoa1910993.
24. Holshue, M.L., DeBolt, C., Lindquist, S., Lofy, K.H., Wiesman, J., Bruce, H., et al. First case of 2019 novel coronavirus in the United States. N Engl J Med, 2020 Jan 31, 10.1056/NEJMoa2001191 [Epub ahead of print].